{"id":20702,"date":"2024-01-16T17:19:47","date_gmt":"2024-01-16T11:49:47","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=20702"},"modified":"2024-01-16T17:19:49","modified_gmt":"2024-01-16T11:49:49","slug":"novartis-steps-back-from-cytokinetics-acquisition","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/","title":{"rendered":"Novartis Steps Back from Cytokinetics Acquisition Amid Stock Plunge"},"content":{"rendered":"
\n
\"Novartis<\/figure>\n<\/div>\n\n\n

Introduction<\/strong><\/h2>\n\n\n\n

In a surprising turn of events, Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics, a US based cardiovascular drug developer. This sudden decision has sent ripples through the market, prompting a significant drop in Cytokinetics’ stock value and leaving investors and industry analysts questioning the future outlook for both companies. The talks between the two companies broke down, further contributing to the uncertainty surrounding the potential deal. While the specific reasons for the withdrawal remain undisclosed, Novartis might consider revisiting the deal in the future, or another suitor could step in to acquire Cytokinetics.<\/p>\n\n\n\n

Market Reaction and Speculation<\/strong> after Novartis Stepback<\/strong><\/h3>\n\n\n\n

The fallout from the failed acquisition talks has left both the companies facing heightened speculation and market volatility. Cytokinetics’ stock, which had more than doubled in value since reports of takeover interests emerged, witnessed a 6% drop in the last two sessions following concerns that a deal with Novartis might not materialize. The sudden unraveling of the deal underscores the dynamic and unpredictable nature of the pharmaceutical sector, where market sentiments can shift rapidly.<\/p>\n\n\n\n

Novartis’ M&A Strategy and Future Moves<\/strong><\/h3>\n\n\n\n

Novartis, grappling with challenges such as the impending loss of patent protection for key products like Entresto, had been seeking new avenues for growth. The decision to step back from the Cytokinetics acquisition raises questions about Novartis’ broader mergers and acquisitions (M&A) strategy. In an interview with CNBC, CEO Vasant Narasimhan had emphasized a focus on smaller acquisitions, with assets valued below USD 5 billion. As the pharmaceutical<\/a> landscape evolves, industry observers will closely watch Novartis for cues regarding its future strategic moves.<\/p>\n\n\n\n

Cytokinetics’ Potential and Analyst Perspectives<\/strong><\/h3>\n\n\n\n

Cytokinetics, with a market capitalization of nearly USD 10 billion, had been seen as an attractive acquisition target. Several market experts have highlighted the potential of Cytokinetics, especially its late-stage trial data for the experimental drug aficamten. The drug, designed to treat hypertrophic cardiomyopathy (HCM), has shown promise and positioned Cytokinetics as a player in the competitive pharmaceutical landscape. The recent setback in the deal, however, has raised questions about how Cytokinetics will navigate its future strategic path.<\/p>\n\n\n\n

Source1: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/novartis-drops-pursuit-cytokinetics-wsj-2024-01-11\/<\/a>
Sourec2: https:\/\/www.bloomberg.com\/news\/features\/2024-01-10\/swiss-pharma-giants-roche-and-novartis-plot-different-paths-to-recovery<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Introduction In a surprising turn of events, Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics, a US based cardiovascular drug developer. This sudden decision has sent ripples through the market, prompting a significant drop in Cytokinetics’ stock value and leaving investors and industry analysts questioning the […]<\/p>\n","protected":false},"author":70,"featured_media":20704,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[486],"tags":[1466,1463,1465,1464],"class_list":["post-20702","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-development","tag-cardiovascular-drug","tag-cytokinetics","tag-hypertrophic-cardiomyopathy","tag-novartis"],"yoast_head":"\nNovartis Steps Back from Cytokinetics Acquisition<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Steps Back from Cytokinetics Acquisition\" \/>\n<meta property=\"og:description\" content=\"Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RootsAnalysis\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-16T11:49:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-16T11:49:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2024\/01\/Roots-Analysis-FeaturedImage-Novartis.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"175\" \/>\n\t<meta property=\"og:image:height\" content=\"43\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Pemba Lahmo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:site\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pemba Lahmo\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/\"},\"author\":{\"name\":\"Pemba Lahmo\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/c2638a51cbfc10884ecca0f902c12b25\"},\"headline\":\"Novartis Steps Back from Cytokinetics Acquisition Amid Stock Plunge\",\"datePublished\":\"2024-01-16T11:49:47+00:00\",\"dateModified\":\"2024-01-16T11:49:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/\"},\"wordCount\":387,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Roots-Analysis-FeaturedImage-Novartis.webp\",\"keywords\":[\"cardiovascular drug\",\"Cytokinetics\",\"hypertrophic cardiomyopathy\",\"Novartis\"],\"articleSection\":[\"DRUG DEVELOPMENT\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/\",\"name\":\"Novartis Steps Back from Cytokinetics Acquisition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Roots-Analysis-FeaturedImage-Novartis.webp\",\"datePublished\":\"2024-01-16T11:49:47+00:00\",\"dateModified\":\"2024-01-16T11:49:49+00:00\",\"description\":\"Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Roots-Analysis-FeaturedImage-Novartis.webp\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Roots-Analysis-FeaturedImage-Novartis.webp\",\"width\":175,\"height\":43,\"caption\":\"This is a feature image for blog article-Novartis at Roots Analysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/novartis-steps-back-from-cytokinetics-acquisition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Steps Back from Cytokinetics Acquisition Amid Stock Plunge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"name\":\"Blog\",\"description\":\"Roots Analysis\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\",\"name\":\"Roots Analysis\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"width\":205,\"height\":61,\"caption\":\"Roots Analysis\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RootsAnalysis\\\/\",\"https:\\\/\\\/x.com\\\/RootsAnalysis\",\"https:\\\/\\\/www.instagram.com\\\/rootsanalysis\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/roots-analysis\\\/\",\"https:\\\/\\\/www.pinterest.it\\\/analysis1340\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCwZF57vY1lnU0bNLej2zukg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/c2638a51cbfc10884ecca0f902c12b25\",\"name\":\"Pemba Lahmo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/36c2acf3152647d45468f8cbfe5a9f02af7681f846c70eb2458b18e945dedb1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/36c2acf3152647d45468f8cbfe5a9f02af7681f846c70eb2458b18e945dedb1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/36c2acf3152647d45468f8cbfe5a9f02af7681f846c70eb2458b18e945dedb1c?s=96&d=mm&r=g\",\"caption\":\"Pemba Lahmo\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novartis Steps Back from Cytokinetics Acquisition","description":"Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/","og_locale":"en_US","og_type":"article","og_title":"Novartis Steps Back from Cytokinetics Acquisition","og_description":"Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics","og_url":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/","og_site_name":"Blog","article_publisher":"https:\/\/www.facebook.com\/RootsAnalysis\/","article_published_time":"2024-01-16T11:49:47+00:00","article_modified_time":"2024-01-16T11:49:49+00:00","og_image":[{"width":175,"height":43,"url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2024\/01\/Roots-Analysis-FeaturedImage-Novartis.webp","type":"image\/webp"}],"author":"Pemba Lahmo","twitter_card":"summary_large_image","twitter_creator":"@RootsAnalysis","twitter_site":"@RootsAnalysis","twitter_misc":{"Written by":"Pemba Lahmo","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/#article","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/"},"author":{"name":"Pemba Lahmo","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/c2638a51cbfc10884ecca0f902c12b25"},"headline":"Novartis Steps Back from Cytokinetics Acquisition Amid Stock Plunge","datePublished":"2024-01-16T11:49:47+00:00","dateModified":"2024-01-16T11:49:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/"},"wordCount":387,"publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2024\/01\/Roots-Analysis-FeaturedImage-Novartis.webp","keywords":["cardiovascular drug","Cytokinetics","hypertrophic cardiomyopathy","Novartis"],"articleSection":["DRUG DEVELOPMENT"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/","url":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/","name":"Novartis Steps Back from Cytokinetics Acquisition","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/#primaryimage"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2024\/01\/Roots-Analysis-FeaturedImage-Novartis.webp","datePublished":"2024-01-16T11:49:47+00:00","dateModified":"2024-01-16T11:49:49+00:00","description":"Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics","breadcrumb":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/#primaryimage","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2024\/01\/Roots-Analysis-FeaturedImage-Novartis.webp","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2024\/01\/Roots-Analysis-FeaturedImage-Novartis.webp","width":175,"height":43,"caption":"This is a feature image for blog article-Novartis at Roots Analysis"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rootsanalysis.com\/blog\/novartis-steps-back-from-cytokinetics-acquisition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rootsanalysis.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Novartis Steps Back from Cytokinetics Acquisition Amid Stock Plunge"}]},{"@type":"WebSite","@id":"https:\/\/www.rootsanalysis.com\/blog\/#website","url":"https:\/\/www.rootsanalysis.com\/blog\/","name":"Blog","description":"Roots Analysis","publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rootsanalysis.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization","name":"Roots Analysis","url":"https:\/\/www.rootsanalysis.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","width":205,"height":61,"caption":"Roots Analysis"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RootsAnalysis\/","https:\/\/x.com\/RootsAnalysis","https:\/\/www.instagram.com\/rootsanalysis\/","https:\/\/www.linkedin.com\/company\/roots-analysis\/","https:\/\/www.pinterest.it\/analysis1340\/","https:\/\/www.youtube.com\/channel\/UCwZF57vY1lnU0bNLej2zukg"]},{"@type":"Person","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/c2638a51cbfc10884ecca0f902c12b25","name":"Pemba Lahmo","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/36c2acf3152647d45468f8cbfe5a9f02af7681f846c70eb2458b18e945dedb1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/36c2acf3152647d45468f8cbfe5a9f02af7681f846c70eb2458b18e945dedb1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/36c2acf3152647d45468f8cbfe5a9f02af7681f846c70eb2458b18e945dedb1c?s=96&d=mm&r=g","caption":"Pemba Lahmo"}}]}},"_links":{"self":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/20702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/users\/70"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/comments?post=20702"}],"version-history":[{"count":2,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/20702\/revisions"}],"predecessor-version":[{"id":20707,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/20702\/revisions\/20707"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media\/20704"}],"wp:attachment":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media?parent=20702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/categories?post=20702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/tags?post=20702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}